Emerging Technologies for Heart Diseases
Volume 2: Treatments for Myocardial Ischemia and Arrhythmias
- 1st Edition - August 19, 2020
- Imprint: Academic Press
- Editor: Udi Nussinovitch
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 3 7 0 4 - 8
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 3 7 0 5 - 5
The increasing pace of advances in cardiology throughout the last few decades has fundamentally altered the natural course of heart patients. In the last few years, available… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe increasing pace of advances in cardiology throughout the last few decades has fundamentally altered the natural course of heart patients. In the last few years, available therapies have been revolutionized completely by new transcatheter therapeutic approaches, novel ventricular assist devices, and new drugs. Also, molecular biology and genetics have a rapidly growing impact on cardiovascular diseases, enabling the field of regenerative medicine to become increasingly closer to routine clinical implementation.
Emerging Technologies for Heart Diseases was conceived to cover the recent extensive literature on current and novel therapeutic options for cardiac patients. The first volume is dedicated to heart failure and valvular disorders, and the second covers myocardial ischemia and arrhythmias. The clinical topic is addressed in several chapters divided according to the therapeutic approach (mechanical or electrical device-based, or cell and gene-based). Each of the 46 chapters focuses on clinically available solutions, new therapies currently under evaluation in clinical trials, promising preclinical technologies, and emerging concepts and innovations that have not yet been tested in a preclinical model. Also, the book discusses future challenges and opportunities for clinical implementation. Lessons learned from abandoned experimental practices are also covered, giving the readers the widest possible perspective of current therapeutic dilemmas.
Overall, this textbook was designed for physicians who want to stay up-to-date with current therapies and those of the future, for biomedical companies, and for those who wish to broaden their knowledge of new cardiovascular therapeutic options.
- Provides a comprehensive review of the latest therapeutic developments for heart failure, valvular disorders, myocardial ischemia and arrhythmias, and their clinical implications
- Written by both specialists in the field and established researchers, it delivers a review of emerging medical technologies and presents insight into their therapeutic promise
- Chapters are arranged according to disease pathogeneses and relevance and include coverage of the mechanical, electrophysiological, and biological approaches for the management of patients with myocardial ischemia and arrhythmias
Biomedical companies and basic scientists who develop biological and device-based approaches for the treatment of heart conditions. Medical professionals who wish to enhance their knowledge of current and emerging medical technologies developed for the treatment of cardiovascular diseases including cardiologists, cardio-thoracic surgeons, internal-medicine specialists. Medical students who are interested in medical advancements will find this book of great interest.
- Cover
- Title page
- Contents
- Copyright
- Dedication
- Contributors
- Preface
- Disclaimer
- Volume 2
- Section 5: Treatment of ischemic heart disease
- Chapter 24: Emerging therapies in coronary balloon angioplasty, stenting, and bioabsorbable scaffolds
- Abstract
- 24.1. Introduction
- 24.2. Historical overview
- 24.3. Emerging therapies in balloon angioplasty
- 24.4. Emerging therapies in coronary stents
- 24.5. Emerging therapies in bioresorbable scaffolds
- 24.6. Emerging therapies in device delivery
- 24.7. Conclusions, future challenges and opportunities
- Chapter 25: Coronary thrombectomy
- Abstract
- 25.1. Introduction
- 25.2. Clinically available solutions
- 25.3. Clinical trials
- 25.4. Emerging innovations
- 25.5. Conclusions, future challenges and opportunities
- Chapter 26: Coronary atherectomy and treatment of calcified disease
- Abstract
- 26.1. Introduction
- 26.2. Pathophysiology of coronary artery calcification
- 26.3. Revascularization strategies
- 26.4. Imaging techniques
- 26.5. Modification of calcific lesions
- 26.6. Atherectomy
- 26.7. Intravascular lithotripsy
- 26.8. Emerging concepts and innovations
- 26.9. Conclusions
- Chapter 27: Treatment of chronic total occlusion
- Abstract
- 27.1. Introduction
- 27.2. Basics of chronic total occlusions
- 27.3. CTO anatomy and histopathology
- 27.4. Procedural considerations
- 27.5. Technical strategies
- Chapter 28: Minimally-invasive device-based approaches for improving cardiac perfusion
- Abstract
- 28.1. Introduction
- 28.2. Clinically available solutions
- 28.3. Clinical trials and experimental treatments
- 28.4. Preclinical technologies
- 28.5. Emerging concepts and innovations
- 28.6. Future challenges and opportunities
- 28.7. Conclusions
- Chapter 29: Gene and protein therapy approaches to cardiac neovascularization and protection from ischemia
- Abstract
- 29.1. Introduction
- 29.2. Clinical trials and experimental treatments
- 29.3. Preclinical technologies
- 29.4. Emerging concepts and innovations
- 29.5. Conclusions, future challenges and opportunities
- Acknowledgments
- Section 6: Treatment and prevention of ventricular tachyarrhythmias
- Chapter 30: The past, present, and future of implantable cardioverter-defibrillators
- Abstract
- 30.1. Introduction—History of the ICD
- 30.2. Clinically available solutions
- 30.3. Clinical trial and experimental treatments
- 30.4. Emerging concepts and innovations
- 30.5. Conclusions, future challenges and opportunities
- Chapter 31: Electrophysiologic mapping and cardiac ablation therapy for prevention of ventricular tachycardia
- Abstract
- 31.1. Introduction
- 31.2. Mechanisms of ventricular tachycardia
- 31.3. Common underlying substrates associated with scar related ventricular tachycardia
- 31.4. Electrophysiologic mapping techniques for ventricular tachycardia
- 31.5. Innovations in electrophysiologic mapping of ventricular tachycardia
- 31.6. Role of catheter ablation in management of ventricular tachycardia
- 31.7. Preclinical technologies
- 31.8. Emerging concepts and innovations
- 31.9. Conclusions, future challenges and opportunities
- Chapter 32: Gene and cell therapy approaches for the prevention and treatment of ventricular arrhythmias
- Abstract
- 32.1. Ventricular arrhythmias
- 32.2. Gene therapy for ventricular arrhythmias
- 32.3. Cell therapy for ventricular arrhythmias
- 32.4. Conclusions
- Section 7: Treatment and prevention of supraventricular tachyarrhythmias
- Chapter 33: Ablation therapy and implantable device based approaches for supraventricular arrhythmias
- Abstract
- 33.1. Introduction
- 33.2. Clinically available solutions
- 33.3. Clinical trials and experimental treatments
- 33.4. Preclinical technologies
- 33.5. Conclusions, future challenges and opportunities
- Chapter 34: Gene and cell based therapies for the prevention and treatment of supraventricular arrhythmias
- Abstract
- 34.1. Introduction
- 34.2. The basic components of myocardial gene transfer
- 34.3. Gene delivery to the myocardium
- 34.4. Clinical outlook of gene vectors and delivery
- 34.5. Gene therapy for atrial fibrillation
- 34.6. Optogenetic rhythm control
- 34.7. Cardiac cell therapy
- 34.8. Future outlook
- Section 8: Treatment and prevention of bradyarrhythmias
- Chapter 35: Cardiac rhythm devices of today and tomorrow
- Abstract
- 35.1. Abbreviated history of the pacemaker
- 35.2. Extending device longevity
- 35.3. Remote monitoring
- 35.4. Leadless pacemaker
- 35.5. His bundle pacing
- 35.6. Conclusions
- Chapter 36: Molecular therapies for bradyarrhythmias
- Abstract
- 36.1. Introduction
- 36.2. The cardiac conduction system and pathophysiology of bradyarrhythmias
- 36.3. Clinically available solutions
- 36.4. Pre-clinical technologies: development of biological pacemakers
- 36.5. Translation towards clinic testing
- 36.6. Conclusions, future challenges and opportunities
- Acknowledgments
- Chapter 37: Cell therapy approaches for treatment of bradyarrhythmias
- Abstract
- 37.1. Introduction
- 37.2. Clinically available solutions—current state of electronic pacing devices
- 37.3. Biological background
- 37.4. Preclinical technologies—generating SA node-like cardiac cells
- 37.5. Emerging concepts and innovations: generating systems-biology-based networks to improve nodal cell generation
- 37.6. Conclusions, future challenges and opportunities
- Acknowledgments
- Chapter 38: Optogenetics for cardiac pacing, resynchronization, and arrhythmia termination
- Abstract
- 38.1. Introduction
- 38.2. Preclinical translational research
- 38.3. Emerging innovations and future challenges
- 38.4. Conclusions
- Acknowledgments
- Chapter 39: Non-optogenetic approaches for leadless cardiac pacing: mechanically induced excitation for extracorporeal control of cardiac rhythm
- Abstract
- 39.1. Introduction
- 39.2. Mechanisms of mechanical pacing
- 39.3. Application of mechanical pacing
- 39.4. Challenges for mechanical pacing
- 39.5. Future directions
- 39.6. Conclusions
- Acknowledgments
- Section 9: Flexible electronics for cardiac monitoring and therapy
- Chapter 40: Organ conformal electronics for cardiac therapeutics
- Abstract
- 40.1. Introduction
- 40.2. Current clinical technologies
- 40.3. Preclinical data and emerging technologies
- 40.4. Clinical capabilities of conformal electronics
- 40.5. Future directions: the next generation of technology
- Section 10: Device-based therapies for prevention of cerebral embolization
- Chapter 41: Embolic protection devices for stroke prevention during cardiac interventions
- Abstract
- 41.1. Introduction
- 41.2. Aortic flow and predisposition for cerebral embolization
- 41.3. Clinically available solutions
- 41.4. Clinical trials and experimental treatments
- 41.5. Preclinical technologies, emerging concepts and innovations
- 41.6. Conclusions, future challenges and opportunities
- Chapter 42: Percutaneous closure of the left atrial appendage for stroke prevention
- Abstract
- 42.1. Introduction
- 42.2. Clinically available solutions
- 42.3. Clinical trials and experimental treatments
- 42.4. Emerging concepts and innovations
- 42.5. Watchman—indications, procedural, and postprocedural considerations
- 42.6. Conclusions, future challenges and opportunities
- Chapter 43: Devices for continuous embolic protection
- Abstract
- 43.1. Introduction
- 43.2. Clinically available solutions
- 43.3. Clinical trials and experimental treatments
- 43.4. Preclinical technologies
- 43.5. Emerging concepts and innovations
- 43.6. Conclusions, future challenges and opportunities
- Acknowledgment
- Section 11: Minimally-invasive methods for structural heart defects
- Chapter 44: Transcatheter closure of atrial septal defect and a patent foramen ovale in adults
- Abstract
- 44.1. Introduction
- 44.2. Atrial septal defects
- 44.3. Percutaneous atrial septal defect closure devices—a success story
- 44.4. Patent foramen ovale
- 44.5. Conclusions, future challenges and opportunities
- Chapter 45: Catheter-based treatments for ventricular septal defects
- Abstract
- 45.1. Introduction
- 45.2. Clinically available solutions: perimembranous ventricular septal defects
- 45.3. Clinically available solutions: muscular ventricular septal defects
- 45.4. Conclusions, future challenges and opportunities
- Section 12: Novel treatments for hypertension
- Chapter 46: Nonpharmacological therapies for uncontrolled hypertension
- Abstract
- 46.1. Introduction to uncontrolled hypertension
- 46.2. Renal denervation
- 46.3. Baroreflex activation therapy (BAT) and endovascular baroreflex amplification (EBA)
- 46.4. Other device-based, emerging approaches
- 46.5. Conclusions
- Index
- Edition: 1
- Published: August 19, 2020
- No. of pages (Hardback): 730
- No. of pages (eBook): 730
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128137048
- eBook ISBN: 9780128137055
UN
Udi Nussinovitch
Udi Nussinovitch, MD, PhD graduated from the Sackler Faculty of Medicine, Tel Aviv University, training at the Sheba Medical Center, Rambam Healthcare Center and Meir Medical Center, while concurrently graduating with a PhD in cardiac electrophysiology from the Technion Institute of Technology, Israel.
Dr Nussinovitch has dedicated his research to investigating novel therapeutic approaches for cardiac disorders and the modulation of the cardiac electrophysiologic substrate for therapeutic purposes. He serves as director of the Applicative Cardiovascular Research Center (ACRC), affiliated to Tel Aviv University.
Dr Nussinovitch founded several biotech companies, and has been the recipient of several research awards. He carries out his clinical work at the Meir Medical Center, a medical facility and leading referral center in Israel.
Affiliations and expertise
Applicative Cardiovascular Research Center (ACRC) and Department of Cardiology, Meir Medical Center, affiliated to Tel Aviv University, IsraelRead Emerging Technologies for Heart Diseases on ScienceDirect